{"id":1068185,"date":"2022-04-13T01:50:17","date_gmt":"2022-04-13T05:50:17","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/apexigen-announces-new-data-from-a-phase-2-trial-evaluating-its-cd40-antibody-sotigalimab-in-combination-with-pembrolizumab-in-patients-with\/"},"modified":"2024-08-18T11:44:00","modified_gmt":"2024-08-18T15:44:00","slug":"apexigen-announces-new-data-from-a-phase-2-trial-evaluating-its-cd40-antibody-sotigalimab-in-combination-with-pembrolizumab-in-patients-with","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/apexigen-announces-new-data-from-a-phase-2-trial-evaluating-its-cd40-antibody-sotigalimab-in-combination-with-pembrolizumab-in-patients-with.php","title":{"rendered":"Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with&#8230;"},"content":{"rendered":"<p><![CDATA[-The combination of intratumoral sotigalimab and systemic pembrolizumab induced broad innate and adaptive immune activation in local and distant tumors-]]><\/p>\n<p>See original here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/04\/12\/2421457\/0\/en\/Apexigen-Announces-New-Data-from-a-Phase-2-Trial-Evaluating-its-CD40-Antibody-Sotigalimab-in-Combination-with-Pembrolizumab-in-Patients-with-Metastatic-Melanoma-Presented-at-the-AA.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with...\">Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See original here: Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with... <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/apexigen-announces-new-data-from-a-phase-2-trial-evaluating-its-cd40-antibody-sotigalimab-in-combination-with-pembrolizumab-in-patients-with.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068185","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068185"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068185"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068185\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}